Sugi Predict

Sugi Predict / Compounds / SCHEMBL959386

SCHEMBL959386

SCHEMBL959386

O=S(=O)(c1ccc(B(O)O)cc1)N1CCCC1

nearest known ligand 0.68

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.68
▸ POLB P06746 2/20 0.58
▸ ALDH1A1 P00352 4/20 0.57
▸ MAPT P10636 2/20 0.57
▸ NPC1 O15118 1/20 0.57
▸ RAB9A P51151 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ GAA P10253 2/20 0.56
▸ PKM P14618 2/20 0.54
▸ LMNA P02545 2/20 0.54
▸ TSHR P16473 1/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ HTT P42858 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1742543 0.98 USP2 (0.71) USP2POLBALDH1A1MAPTNPC1
SCHEMBL289460 0.96 USP2 (0.62) USP2POLBALDH1A1MAPTNPC1
SCHEMBL2075760 0.86 APOBEC3A (0.68) USP2POLBALDH1A1RAB9ASMN1; SMN2
SCHEMBL477530 0.84 POLB (0.67) USP2POLBALDH1A1SMN1; SMN2LMNA
SCHEMBL144421 0.84 POLB (0.67) USP2POLBALDH1A1SMN1; SMN2GAA
SCHEMBL4006404 0.84 L3MBTL1 (0.58) USP2ALDH1A1MAPTNPC1RAB9A
SCHEMBL4002911 0.83 KMT2A (0.49) USP2POLBALDH1A1NPC1GAA
SCHEMBL4717212 0.82 USP2 (0.50) USP2POLBALDH1A1MAPTNPC1
SCHEMBL4009686 0.82 CYP2D6 (0.49) USP2POLBALDH1A1SMN1; SMN2PKM
SCHEMBL519915 0.81 ALDH1A1 (0.65) USP2ALDH1A1MAPTSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1575942-B1 COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 ASTRAZENECA AB (SE) 2007-05-02 — — EP claimed
US-20060173014-A1 Nobel compounds having selective inhibiting effect at gsk3 ASTRAZENECA AB (SE) 2006-08-03 — — US claimed
US-20060116385-A1 Novel compounds having selective inhibiting effect at gsk3 ASTRAZENECA AB (SE) 2006-06-01 — — US claimed
JP-2006512337-A — — 2006-04-13 — — JP claimed
US-20060052396-A1 Arylamines for the treatment of conditions associated with gsk-3 ASTRAZENECA (SE) 2006-03-09 — — US claimed
EP-1575942-A1 NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 AstraZeneca AB (SE) 2005-09-21 — — EP claimed
EP-1575939-A1 NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 AstraZeneca AB (SE) 2005-09-21 — — EP claimed
WO-2004055009-A1 NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 ASTRAZENECA AB (SE) 2004-07-01 — — WO claimed
WO-2004055006-A1 NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 ASTRAZENECA AB (SE) 2004-07-01 — — WO claimed
EP-1414801-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 AstraZeneca AB (SE) 2004-05-06 — — EP claimed
WO-2003004472-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 ASTRAZENECA AB (SE) 2003-01-16 — — WO claimed
US-12202818-B2 Compounds and methods for CD73 modulation and indications therefor Opna Bio SA (CH) 2025-01-21 — — US disclosed
US-20240408169-A1 CYCLIN INHIBITORS CIRCLE PHARMA, INC. 2024-12-12 — — US disclosed
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2024-10-17 — — US disclosed
EP-4139296-B1 COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR Opna Bio SA (CH) 2024-09-18 — — EP disclosed
EP-1575942-A1 NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 AstraZeneca AB (SE) 2005-09-21 — — EP disclosed
WO-2004055009-A1 NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFECT AT GSK3 ASTRAZENECA AB (SE) 2004-07-01 — — WO disclosed
WO-2004055006-A1 NOVEL COMPOUNDS HAVING SELECTIVE INHIBITING EFFECT AT GSK3 ASTRAZENECA AB (SE) 2004-07-01 — — WO disclosed
EP-1414801-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 AstraZeneca AB (SE) 2004-05-06 — — EP disclosed
WO-2003004472-A1 ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 ASTRAZENECA AB (SE) 2003-01-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12202818-B2 Compounds and methods for CD73 modulation and indications therefor ENTPD5, ENTPD1, ADORA2A USP2 4655/4885POLB 1748/4885ALDH1A1 208/4885
US-20240408169-A1 CYCLIN INHIBITORS CCNI, CDK2, CDK1 USP2 2232/4885POLB 110/4885ALDH1A1 2367/4885
US-20060173014-A1 Nobel compounds having selective inhibiting effect at gsk3 GSK3B, GSK3A, GSKIP USP2 1984/4885POLB 2373/4885ALDH1A1 4130/4885
US-20060116385-A1 Novel compounds having selective inhibiting effect at gsk3 GSK3B, GSK3A, NR5A2 USP2 3092/4885POLB 3741/4885ALDH1A1 4529/4885
US-20060052396-A1 Arylamines for the treatment of conditions associated with gsk-3 GSK3A, GSK3B, PYGL USP2 3860/4885POLB 2675/4885ALDH1A1 2625/4885
US-20240343704-A1 HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) CMPK1, WNK1, AAK1 USP2 2851/4885POLB 2343/4885ALDH1A1 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.